ライフサイエンスコーパス: COPD exacerbation

1 on symptom, is useful in the confirmation of COPD exacerbation.

2 sthma exacerbation and 131,974 patients with COPD exacerbation.

3 ts with asthma exacerbation and 162,899 with COPD exacerbation.

4 s conducted among hospitalized patients with COPD exacerbation.

5 the hospital stay in patients with recurrent COPD exacerbation.

6 s with persistent hypercapnia after an acute COPD exacerbation.

7 mg/L initiated 14 (+/-3) days after an index COPD exacerbation.

8 was the time to the first moderate or severe COPD exacerbation.

9 h increased respiratory symptoms and risk of COPD exacerbation.

10 and biologically relevant marker to predict COPD exacerbations.

11 ondary bacterial infections in virus-induced COPD exacerbations.

12 as important cellular targets in controlling COPD exacerbations.

13 al inflammation and ameliorate virus-induced COPD exacerbations.

14 ve drugs for the prevention and treatment of COPD exacerbations.

15 rticosteroids in the outpatient treatment of COPD exacerbations.

16 n improve outcomes in patients with frequent COPD exacerbations.

17 ynamic temporal change in airway SPMs during COPD exacerbations.

18 Exposure to air pollutants may trigger COPD exacerbations.

19 therapy with antibiotic/antiviral agents for COPD exacerbations.

20 care quality for patients hospitalized with COPD exacerbations.

21 transcriptome of circulating leukocytes and COPD exacerbations.

22 r use may be associated with reduced risk of COPD exacerbations.

23 uggest that MUC5AC inhibition may ameliorate COPD exacerbations.

24 s strategy and its role in the management of COPD exacerbations.

25 OPD or respiratory events, and treatment for COPD exacerbations.

26 has a functional role in the pathogenesis of COPD exacerbations.

27 models that perform short-term prediction of COPD exacerbations.

28 IL-17C production and its potential role in COPD exacerbations.

29 g NIV failure (25-15%) in severe hypercapnic COPD exacerbations.

30 inophilic airway inflammation contributes to COPD exacerbations.

31 e primary outcome was the annual rate of all COPD exacerbations.

32 hree dihexosylceramides were associated with COPD exacerbations.

33 a and glycosphingolipids are associated with COPD exacerbations.

34 d with a clinically significant reduction in COPD exacerbations.

35 ses in nocturnal symptoms and risk of severe COPD exacerbations.

36 f teeth and thus may reduce the frequency of COPD exacerbations.

37 s, rescue medication use, and risk of severe COPD exacerbations.

38 h increased respiratory symptoms and risk of COPD exacerbations.

39 ry tract contributes to approximately 50% of COPD exacerbations.

40 atio] of >1) would be associated with severe COPD exacerbations.

41 acute chronic obstructive pulmonary disease (COPD) exacerbation.

42 er of chronic obstructive pulmonary disease (COPD) exacerbations.

43 se of chronic obstructive pulmonary disease (COPD) exacerbations.

44 se of chronic obstructive pulmonary disease (COPD) exacerbations.

45 auses chronic obstructive pulmonary disease (COPD) exacerbations.

46 F) or chronic obstructive pulmonary disease (COPD) exacerbations.

47 duced chronic obstructive pulmonary disease (COPD) exacerbations.

48 9 (2.1-38), 23 (8.8-58), and 36 (12-105) for COPD exacerbations; 1.5 (0.9-2.2), 1.6 (1.0-2.4), and 2.

49 d to harm 54) and the hazard of first severe COPD exacerbation 29% higher (1.29 (1.12 to 1.48); numbe

50 ropium patients were hospitalized because of COPD exacerbation (7.0% vs. 9.5%, respectively; differen

51 c steroids and antibiotics should be used in COPD exacerbations according to the usual indications.

52 predictive value [NPV]; treatment efficacy (COPD exacerbations, all-cause mortality, quality of life

53 with chronic obstructive pulmonary disease (COPD) exacerbations among individuals with COPD in the g

54 or raised C-reactive protein 14 days after a COPD exacerbation, an additional course of ciprofloxacin

55 atants and plasma from patients experiencing COPD exacerbation and healthy control subjects.

56 oints were the percentage of patients with a COPD exacerbation and the percentage of patients with a

57 roup performed telephone-based assessment of COPD exacerbations and hospitalizations, and all hospita

58 tibiotic treatment has been shown to prevent COPD exacerbations and hospitalizations.

59 rial reported that metoprolol did not reduce COPD exacerbations and increased COPD exacerbations requ

60 wing experimental rhinovirus (RV)-16-induced COPD exacerbations and its relationship to disease sever

61 Tiotropium reduces COPD exacerbations and may reduce related health care ut

62 Blood fibrocytes are recruited during COPD exacerbations and related to mortality and low lung

63 Inflammatory cytokines linked to COPD exacerbations and severe COVID-19 were increased, w

64 r without inhaled corticosteroids can reduce COPD exacerbations and tiotropium can improve health-rel

65 d reduce the incidence of moderate or severe COPD exacerbations and upper respiratory infections.

66 uring chronic obstructive pulmonary disease (COPD) exacerbations and is a plausible target for MAIT c

67 Adjusted risks of asthma exacerbation, COPD exacerbation, and hospitalization for heart failure

68 iveness outcome was first moderate or severe COPD exacerbation, and the primary safety outcome was fi

69 into the potential immune pathophysiology of COPD exacerbations, and indicate that NK cell phenotypin

70 h asthma had an increased risk of asthma and COPD exacerbations, and possibly pneumonias.

71 PD, a 50-pack-year smoking history, frequent COPD exacerbations, and recurrent pneumonia.

72 a and chronic obstructive pulmonary disease (COPD) exacerbation, and hospitalization due to heart fai

73 COPD exacerbations are associated with increased airway

74 COPD exacerbations are most often associated with viral

75 nale: Chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of morbidity and m

76 Chronic obstructive pulmonary disease (COPD) exacerbations are associated with virus (mostly rh

77 nt of chronic obstructive pulmonary disease (COPD) exacerbations are lacking.

78 nale: Chronic obstructive pulmonary disease (COPD) exacerbations are prone to nonrecovery, but there

79 after chronic obstructive pulmonary disease (COPD) exacerbations are recognized.

80 es: To assess whether incompletely recovered COPD exacerbations benefit from additional treatment wit

81 ents did not cause a significant increase in COPD exacerbations, but did reduce total systemic cortic

82 rker to direct corticosteroid therapy during COPD exacerbations, but larger studies are required.

83 t IL-17C may contribute to microbial-induced COPD exacerbations by promoting neutrophil recruitment.

84 ondary endpoints included the rate of severe COPD exacerbations, change in quality of life (St.

85 Participants were recruited from the London COPD Exacerbation Cohort between January 11, 2016, and A

86 Objective: To evaluate the impact of TLD on COPD exacerbations compared with optimal medical treatme

87 as superior in preventing moderate to severe COPD exacerbations compared with the single longacting a

88 Chronic obstructive pulmonary disease (COPD) exacerbations contribute significantly to morbidit

89 Measurements and Main Results: Unadjusted COPD exacerbation counts were lower in GLP-1RA users.

90 lycopyrronium for rate of moderate to severe COPD exacerbations (defined by worsening symptoms and ca

91 he percentages of individuals experiencing a COPD exacerbation during the first year of observation w

92 in adults aged >=50 years and those with CHF/COPD exacerbations during the 2018-2020 seasons.

93 tcome measures were first moderate or severe COPD exacerbation (effectiveness) and first admission to

94 cal phenomenon that results in more frequent COPD exacerbation events, contributing to disease progre

95 , little understanding of immune function in COPD exacerbations exists.

96 ing the first 2 hrs of treatment of an acute COPD exacerbation failed to improve FEV1 faster than the

97 COPD exacerbation frequency was related to stable-state

98 ng emphysema percentage were associated with COPD exacerbation frequency.

99 who were admitted with a diagnosis of acute COPD exacerbation from December 2016 to June 2019 and wh

100 quent chronic obstructive pulmonary disease (COPD) exacerbation has been associated with the isolatio

101 l for chronic obstructive pulmonary disease (COPD) exacerbation have impaired quality of life and fre

102 d for chronic obstructive pulmonary disease (COPD) exacerbations have high rehospitalization rates an

103 higher incidence of first moderate or severe COPD exacerbation (hazard ratio 1.09 (95% CI 1.04 to 1.1

104 a similar hazard of first moderate or severe COPD exacerbation (hazard ratio [HR], 1.03; 95% confiden

105 with respect to the first moderate or severe COPD exacerbation (hazard ratio, 1.06; 95% CI, 0.94 to 1

106 of participants having a moderate or severe COPD exacerbation (hazard ratio, 1.268; 95% confidence i

107 n the reduction of hospital readmissions for COPD exacerbations, health systems in the USA struggle t

108 ) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the

109 for an average period of 4.3 years regarding COPD exacerbations, hospital admissions, and mortality.

110 tion in the rate of first moderate or severe COPD exacerbation (HR, 0.92; 95% CI, 0.89-0.96) and a 20

111 COPD exacerbations impair quality of life and are charac

112 nt of chronic obstructive pulmonary disease (COPD) exacerbations improves outcomes; however, response

113 nd adjusted VE against influenza-related CHF/COPD exacerbation in adults >=18 years was 80.3% (36.3-9

114 ease stages III-IV, and one or more moderate COPD exacerbation in the past year) were randomly assign

115 as diarrhea in the ivacaftor group and acute COPD exacerbation in the placebo group.

116 re diarrhea in the ivacaftor group and acute COPD exacerbation in the placebo group.

117 ss than 50%, at least one moderate-to-severe COPD exacerbation in the previous 12 months, and a COPD

118 wer than 50%, one or more moderate-to-severe COPD exacerbation in the previous 12 months, COPD Assess

119 The frequency of COPD exacerbation in the prior year was determined by us

120 lung microenvironment on rhinovirus-induced COPD exacerbation in vivo.

121 oviruses) were detected in 66 (39.2%) of 168 COPD exacerbations in 53 (64%) patients.

122 chment biomarker for all-cause mortality and COPD exacerbations in July 2015.

123 ve than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerb

124 Conclusions: Prospective studies of COPD exacerbations in patients with comorbid T2D are war

125 approach for the treatment and prevention of COPD exacerbations in the future.

126 ment Test [CAT] >/=10 vs <10) in addition to COPD exacerbations in the previous year (<2 vs >/= 2), a

127 s associated with 8.7% of outpatient-managed COPD exacerbations in this study.

128 stand chronic obstructive pulmonary disease (COPD) exacerbations in people with COPD.

129 d airway wall thickness were associated with COPD exacerbations, independent of the severity of airfl

130 ency of RSV-related community infections and COPD exacerbations is important for vaccine deployment d

131 from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound

132 for a chronic obstructive pulmonary disease (COPD) exacerbation, less is known about PR's impact in r

133 ded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (

134 n in COPD and is associated with more severe COPD exacerbations, lower airway bacterial colonization,

135 nic underlying symptoms or those of an acute COPD exacerbation may be challenging.

136 Among 99 patients with COPD exacerbation (mean [SD] age, 70.6 [9.5] years; 56 w

137 pt that bacteria infecting the airway during COPD exacerbations mediate increased airway inflammation

138 onist ameliorated immunopathology in a mouse COPD exacerbation model.

139 lity evidence) and after hospitalization for COPD exacerbation (moderate-quality evidence), strong re

140 inophil count is associated with the risk of COPD exacerbations, mortality, decline in FEV1, and resp

141 usions: Cardiovascular events after moderate COPD exacerbations occur slightly later than after sever

142 uenzae strains isolated from patients during COPD exacerbations often induce more airway inflammation

143 The index date was the date of first COPD exacerbation or, for those without exacerbations, d

144 ADRB2 polymorphisms differentially affected COPD exacerbation outcomes in response to tiotropium ver

145 ed during the 6MST was a strong predictor of COPD exacerbation over a 36-month follow-up.

146 at tiotropium may lengthen the time to first COPD exacerbation (P = 0.028) and reduce health care uti

147 018), but no evidence of an association with COPD exacerbations (p=0.35) or the other indices of COPD

148 Therefore, supplementation may prevent COPD exacerbations, particularly in deficient patients.

149 is common and clinically significant during COPD exacerbations, particularly in those with underlyin

150 set a premise for a predictive framework in COPD exacerbations, particularly investigating the poten

151 Arterial stiffness rises acutely during COPD exacerbations, particularly with airway infection.

152 nting to the emergency department with acute COPD exacerbation, past or present smokers (>/=20 pack-y

153 The number of COPD exacerbations per patient (primary outcome) was 2.5

154 ith a chronic obstructive pulmonary disease (COPD) exacerbation, pneumonia, and acute decompensated h

155 ma or chronic obstructive pulmonary disease (COPD) exacerbations, pneumonias, lung cancer, ischemic h

156 with ciprofloxacin for incompletely resolved COPD exacerbations prolonged the time until the next eve

157 tware, could estimate joint heterogeneity in COPD exacerbation rate and severity and can have applica

158 The COPD exacerbation rate did not differ between the groups

159 he primary efficacy end point was the annual COPD exacerbation rate during the first year of treatmen

160 ondary endpoints included moderate-to-severe COPD exacerbation rate over 52 weeks.

161 The primary endpoint was moderate-to-severe COPD exacerbation rate.

162 5% CI, 0.34-1.66; P = .48), or treatment for COPD exacerbations (rate ratio, 1.01; 95% CI, 0.53-1.91;

163 ns (rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD exacerbations (rate ratio, 1.08; 95% CI, 0.98 to 1.

164 ether GLP-1RA use is associated with reduced COPD exacerbation rates, and severe and moderate exacerb

165 United States seem to be at greater risk for COPD exacerbation-related mortality than those living in

166 .5; P < 0.05), and to have increased risk of COPD exacerbation requiring an acute doctor visit (OR, 1

167 The risk of COPD exacerbation requiring hospitalization in the 0- to

168 m Short-Form Physical Component (SF-12), and COPD exacerbations requiring health care utilization, ad

169 not reduce COPD exacerbations and increased COPD exacerbations requiring hospital admission.

170 ough (OR, 4.20; P = 0.03), increased risk of COPD exacerbations requiring treatment with antibiotics

171 l did not reduce the number of self-reported COPD exacerbations requiring treatment with oral cortico

172 The most common serious adverse events were COPD exacerbation resulting in admission to hospital (ei

173 barriers could improve adherence and affect COPD exacerbations, spending, or racial disparities in t

174 ed Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlle

175 Glycopyrronium vs. Fluticasone Salmeterol on COPD Exacerbations) study used the Exacerbations of COPD

176 l Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily lon

177 fic clinical phenotypes, biomarkers in early COPD, exacerbation subtype biomarkers, and biomarkers to

178 ug vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose

179 d 6.5 months after randomization (defined as COPD exacerbation, tachypnea, wheezing, worsening bronch

180 uticasone in reducing the annual rate of all COPD exacerbations; the rate was 11% lower in the indaca

181 ison of time to the first moderate or severe COPD exacerbation through 12 months between the treatmen

182 ty <0.7; FEV1 <80% predicted) and at least 2 COPD exacerbations treated with oral corticosteroids, an

183 l outcome was the number of patient-reported COPD exacerbations treated with oral corticosteroids, an

184 The primary outcome of patient-reported COPD exacerbations treated with oral corticosteroids, an

185 of the use of azithromycin for prevention of COPD exacerbations (United States and Canada, 2006-2010;

186 The hazard of first moderate COPD exacerbation was 7% higher (1.07 (1.02 to 1.12); nu

187 Time to first severe COPD exacerbation was a prespecified endpoint; post hoc

188 r beta-blocker use, the time until the first COPD exacerbation was similar in the metoprolol group an

189 COPD exacerbation was the most common serious adverse ev

190 An experimental human model of COPD exacerbation was used to investigate the levels of

191 versus salmeterol-fluticasone on the rate of COPD exacerbations was independent of the baseline blood

192 The rate of moderate to severe COPD exacerbations was reduced over the first year.

193 A total of 215 patients hospitalized for a COPD exacerbation were randomized at hospital discharge

194 Twenty-seven patients presenting with acute COPD exacerbation were studied.

195 Participants hospitalized with COPD exacerbations were assigned 1:1 to receive either u

196 Subjects with COPD exacerbations were entered into a randomized biomar

197 , 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded.

198 4 patients and 965 observations of recurrent COPD exacerbations were selected.

199 se of chronic obstructive pulmonary disease (COPD) exacerbation were examined by monitoring changes i

200 In subjects with COPD, exacerbations were associated with excess FEV1 dec

201 and reduced inflammation in a model of viral COPD exacerbation, which do not affect viral clearance.

202 re are no biomarkers to objectively diagnose COPD exacerbations, which are the major drivers of hospi

203 Literature predictive models for COPD exacerbations, while promising, may be constrained

204 n rates after an index hospitalization for a COPD exacerbation will be penalized with reduced reimbur

205 Outpatient treatment of acute COPD exacerbation with prednisone accelerates recovery o

206 In the COPD exacerbation with respiratory acidosis group, the p

207 With 4365 COPD patients per arm, the HR of a COPD exacerbation with triple therapy vs dual bronchodil

208 Inclusion criteria were COPD exacerbations with PaCO2 >/= 45 mm Hg, pH </= 7.35,

209 d iron were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferri

210 as the incidence of first moderate or severe COPD exacerbation within 365 days of cohort entry.

211 atients discharged after hospitalization for COPD exacerbation would improve quality of life, using t